olodaterol hydrochloride (BioDeep_00000788949)
代谢物信息卡片
化学式: C21H27ClN2O5 (422.1608)
中文名称: 盐酸奥洛他特罗
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O.Cl
InChI: /m0./s1
描述信息
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
Olodaterol (BI1744) hydrochloride is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis[1][2][3].
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:83309
- KEGGdrug: D10020
- PubChem: 11711522
- ChEMBL: CHEMBL2105743
- CAS: 869477-96-3
- medchemexpress: HY-14301A
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Le Wang, Zhaobin Lei, Guanjie Zhang, Yang Cheng, Mingwei Zhong, Guangyong Zhang, Sanyuan Hu. Olodaterol promotes thermogenesis in brown adipocytes via regulation of the β2-AR/cAMP/PKA signaling pathway.
Biochemical and biophysical research communications.
2024 Apr; 703(?):149689. doi:
10.1016/j.bbrc.2024.149689. [PMID: 38382361] - Meng-Jer Hsieh, Ning-Hung Chen, Shih-Lung Cheng, Chi-Wei Tao, Yu-Feng Wei, Yao-Kuang Wu, Ming-Cheng Chan, Shih-Feng Liu, Wu-Huei Hsu, Tsung-Ming Yang, Ming-Shian Lin, Ching-Lung Liu, Ping-Hung Kuo, Ying-Huang Tsai. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
International journal of chronic obstructive pulmonary disease.
2022; 17(?):967-976. doi:
10.2147/copd.s353799. [PMID: 35510163] - Zhenlei Wang, Yusuke Tadayasu, Na Hu, Shiqing Shu, Chao Hu, Zhu Luo. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
Pulmonary pharmacology & therapeutics.
2020 08; 63(?):101944. doi:
10.1016/j.pupt.2020.101944. [PMID: 32916296] - Craig LaForce, Eric Derom, Ulrich Bothner, Isabel M Kloer, Matthias Trampisch, Roland Buhl. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
International journal of chronic obstructive pulmonary disease.
2018; 13(?):1819-1831. doi:
10.2147/copd.s161489. [PMID: 29910611] - Jens Markus Borghardt, Benjamin Weber, Alexander Staab, Christina Kunz, Charlotte Kloft. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
British journal of clinical pharmacology.
2016 09; 82(3):739-53. doi:
10.1111/bcp.12999. [PMID: 27145733] - Jens Markus Borghardt, Benjamin Weber, Alexander Staab, Christina Kunz, Stephan Formella, Charlotte Kloft. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.
British journal of clinical pharmacology.
2016 Mar; 81(3):538-52. doi:
10.1111/bcp.12780. [PMID: 26348533] - Christina Kunz, Doreen Luedtke, Anna Unseld, Alan Hamilton, Atef Halabi, Martina Wein, Stephan Formella. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
International journal of chronic obstructive pulmonary disease.
2016; 11(?):585-95. doi:
10.2147/copd.s94234. [PMID: 27051282] - Zdenek Chundela, Joachim Große. Olodaterol and vilanterol detection in sport drug testing.
Drug testing and analysis.
2015 Nov; 7(11-12):980-2. doi:
10.1002/dta.1918. [PMID: 26593301] - J A van Noord, J J Smeets, B M Drenth, J Rascher, A Pivovarova, A L Hamilton, P J G Cornelissen. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
Pulmonary pharmacology & therapeutics.
2011 Dec; 24(6):666-72. doi:
10.1016/j.pupt.2011.07.006. [PMID: 21839850] - Paola Casarosa, Ines Kollak, Tobias Kiechle, Angela Ostermann, Andreas Schnapp, Ralf Kiesling, Michael Pieper, Peter Sieger, Florian Gantner. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
The Journal of pharmacology and experimental therapeutics.
2011 Jun; 337(3):600-9. doi:
10.1124/jpet.111.179259. [PMID: 21357659]
